(lp0
S'SANGAMO THERAPEUTICS, INC.  Files An 8-K Departure of Directors ... Market Exclusive - 7 hours ago On March 14, 2017, the Compensation Committee of the Board of Directors of Sangamo Therapeutics, Inc.  adopted an Executive Severance Plan .'
p1
aS'Sangamo Therapeutics Announces Presentation At The Cowen And Company 37th ... PR Newswire  - Mar 1, 2017 RICHMOND, Calif., March 1, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. , the leader in therapeutic genome editing, announced today that Sandy Macrae, M.B.'
p2
aS'Sangamo Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results PR Newswire  - Feb 28, 2017 &quot;Early this year we rebranded our company as Sangamo Therapeutics, underscoring our focus on clinical development of genomic therapies using our industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy,&quot;&nbsp;...SANGAMO THERAPEUTICS, INC.  Files An 8-K Results of Operations ... - Market Exclusive'
p3
aS'Sangamo Therapeutics Announces Fourth Quarter And Full Year 2016 Conference ... PR Newswire  - Feb 21, 2017 RICHMOND, Calif., Feb. 21, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. , the leader in therapeutic genome editing, announced today that the company will release its fourth quarter and full year 2016 financial results before the market&nbsp;...'
p4
aS'Sangamo Therapeutics Receives Rare Pediatric Disease Designation From FDA For ... PR Newswire  - Feb 27, 2017 RICHMOND, Calif., Feb. 27, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. , the leader in therapeutic genome editing, today announced that the U.S.Sangamo  Announces Rare Pediatric Disease Designation From FDA For SB-318 - StreetInsider.com'
p5
aS'Sangamo Therapeutics Inc. MarketWatch - Dec 21, 2009 Check out the returns on our 8 Lazy Portfolios that are made up of low-cost buy-and-hold index funds.  How to create your own Lazy Portfolio.'
p6
aS'Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-913 ... PR Newswire  - Mar 1, 2017 RICHMOND, Calif., March 1, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. , the leader in therapeutic genome editing, announced today that the U.S.'
p7
aS'Sangamo Therapeutics, Inc. : How technical signals have emerged? Post Analyst - 11 hours ago Sangamo Therapeutics, Inc.  traded at an unexpectedly low level on 03/17/2017 when the stock experienced a -3.45% loss to a closing price of $4.2.Sangamo Therapeutics  Reaches $4.30 After 6.00% Up Move; Idt (IDT ... - Wolcott Daily'
p8
aS'Price Target Roundup on Keryx Biopharmaceuticals, Inc.  Sangamo ... Rives Journal - 13 hours ago Sell-side analysts are offering a consensus Buy rating on shares of Keryx Biopharmaceuticals, Inc. . Using the following ratings scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell and 5.0 Strong Sell, analysts have an average&nbsp;...'
p9
aS'Investor Review: Focusing in on Shares of Sangamo Therapeutics Inc  Davidson Register - 11 hours ago Active traders have a wide variety of technical indicators at their disposal for completing technical stock analysis. Presently, the 14-day ATR for Sangamo Therapeutics Inc  is spotted at 0.25. First developed by J. Welles Wilder, the ATR may ...'
p10
a.